Should Fallopian Tubes Be Removed During Hysterectomy?
Yes, opportunistic salpingectomy should be performed at the time of hysterectomy for benign indications to reduce the risk of ovarian cancer, as this is safe, does not increase complications, and provides meaningful cancer prevention benefits. 1
Rationale for Routine Salpingectomy
The recommendation for opportunistic salpingectomy is based on the understanding that many high-grade serous ovarian cancers originate in the fallopian tubes rather than the ovaries themselves. By removing the tubes during hysterectomy (when they would otherwise serve no further function), you can reduce ovarian cancer risk without the need for oophorectomy and its associated consequences of surgical menopause.
Key benefits include:
- Reduces ovarian cancer risk by preventing 1 cancer diagnosis per 225 women and 1 cancer death per 450 women undergoing surgery 2
- Does not increase major complication rates meaningfully (7.95% vs 7.68% for hysterectomy alone) 2
- Does not affect ovarian function based on serum markers 1
- Actually reduces overall costs due to decreased need for future adnexal surgery 2
- Safe across all surgical approaches (abdominal, laparoscopic, robotic) 1
Surgical Approach Considerations
For vaginal hysterectomy specifically: Salpingectomy is feasible in approximately 81% of cases when attempted 3. It adds only 11 minutes to operative time and 6 mL of additional blood loss 3. However, completion rates are lower via the vaginal route (13%) compared to laparoscopic (70%), robotic (73%), or open approaches (65%) 4.
Factors that may limit vaginal salpingectomy:
- Prior adnexal surgery (odds ratio 2.9)
- Uterine fibroids (odds ratio 5.8)
- Tubes positioned high in the pelvis
- Bowel or sidewall adhesions 3
Important caveat: The planned route of hysterectomy should NOT be altered to accommodate salpingectomy. Continue using minimally invasive techniques as clinically appropriate 1.
Special Populations
For women with hereditary cancer syndromes (BRCA1/2, Lynch syndrome, etc.): The guidelines differ significantly. These patients require risk-reducing bilateral salpingo-oophorectomy (RRBSO), not just salpingectomy, as they face substantially elevated ovarian cancer risk (44% for BRCA1, 17% for BRCA2) 5. Hysterectomy is not routinely recommended at the time of RRBSO unless there are additional indications such as Lynch syndrome genes (MLH1, MSH2, MSH6) or other risk factors for endometrial cancer 5.
Informed Consent Discussion
When counseling patients, explicitly discuss:
- What salpingectomy does: Reduces but does not eliminate ovarian cancer risk
- What it doesn't do: Does not provide the same protection as bilateral salpingo-oophorectomy
- Safety profile: Minimal increase in complications (approximately 0.61 additional complications per cancer prevented) 2
- Ovarian function: Preserved after salpingectomy alone
- Alternative of oophorectomy: Should be mentioned but generally avoided in premenopausal women due to increased risks of cardiovascular disease, osteoporosis, cognitive impairment, and all-cause mortality 1
Clinical Algorithm
For average-risk women undergoing hysterectomy for benign indications:
- Offer opportunistic bilateral salpingectomy as standard practice
- Proceed with salpingectomy via the planned surgical route
- If vaginal approach and tubes cannot be safely accessed, do not convert to another route solely for tube removal
- Document discussion and decision in operative consent
For high-risk women (genetic mutations):
- Refer to genetics/high-risk clinic for comprehensive evaluation
- Consider RRBSO at appropriate age based on specific mutation
- Add hysterectomy only if Lynch syndrome or other endometrial cancer risk factors present 5, 6
The evidence strongly supports routine opportunistic salpingectomy as a cancer prevention strategy that is both safe and cost-effective, with the trade-off between minimal additional complications and meaningful cancer prevention being highly favorable 1, 2.